Company Clinomics Inc.

Equities

A352770

KR7352770002

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per Business

Sector Other Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 18:00:00 2024-05-02 EDT			5-day change	1st Jan Change
1,765 ^KRW	+1.44%		-1.89%	-31.19%

05-03	Clinomics Inc. agreed to acquire New Oriental Hotel Co., Ltd from Daon Engineering Co., Ltd and Gi-dong Song for KRW 18.5 billion.	CI
2023	Clinomics Inc. announced that it expects to receive KRW 15 billion in funding from Busan Equity Partners Co., Ltd.	CI

Clinomics Inc is a Korea-based company engaged in the development of genome diagnostic tests and liquid biopsies. The Company's main businesses are multi-omics-based service business and liquid biopsy-based cancer diagnosis and screening business. The multi-omics-based service business provides products and services that predict physical characteristics and diseases based on genome diagnosis and tests, and provides early diagnosis services for major diseases such as cancer based on multi-omics. The liquid biopsy-based cancer diagnosis and screening business sells medical devices that diagnose patients by extracting blood cells and deoxyribonucleic acid (DNA), and diagnostic and monitoring kits for cancer mutations in patients. It is also develops products that diagnoses cancer early with blood.

Number of employees: 71

KRW in Million	2022	Weight	2023	Weight	Delta
Bio 62.0 %	-	-	7,077	62.0 %	-
Food and Food Service 36.7 %	-	-	4,186	36.7 %	-
Other 1.3 %	-	-	144	1.3 %	-
Investment 0.0 %	-	-	1	0.0 %	-

KRW in Million	2022	Weight	2023	Weight	Delta
South Korea 100.0 %	23,083	100.0 %	11,408	100.0 %	-50.58%

Managers	Title	Age	Since
Jong-Tae Jung CEO	Chief Executive Officer	62	21-03-23
Byung-Chul Kim CEO	Chief Executive Officer	59	11-06-20
Sung-Hun Lee CTO	Chief Tech/Sci/R&D Officer	47	19-12-31
Jong-Hwa Park BRD	Director/Board Member	57	18-08-31

Members of the board	Title	Age	Since
Byung-Chul Kim CEO	Chief Executive Officer	59	11-06-20
Jong-Hwa Park BRD	Director/Board Member	57	18-08-31
Jong-Tae Jung CEO	Chief Executive Officer	62	21-03-23

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	33,246,263	27,901,805 ( 83.92 %)	3,948 ( 0.0119 %)	83.92 %
Stock B	0	572,518	0	0

Name	Equities	%	Valuation
Jong-Hwa Park 7.379 %	2,453,373	7.379 %	3 M ₩
AMICOGEN, INC. 3.518 %	1,169,490	3.518 %	1 M ₩
Byeong-Cheol Kim 1.610 %	535,388	1.610 %	666 922 ₩
CLINOMICS INC. 1.309 %	435,029	1.309 %	541 907 ₩
Byung-Chul Kim 0.5791 %	192,529	0.5791 %	239 830 ₩
Su-wan Cho 0.5509 %	183,159	0.5509 %	228 158 ₩
SALTLUX INC. 0.4283 %	142,394	0.4283 %	177 377 ₩
Jong-Tae Jung 0.3500 %	116,350	0.3500 %	144 935 ₩
Yong-Chul Shin 0.2790 %	92,766	0.2790 %	115 557 ₩
Sung-hoon Lee 0.0693 %	23,031	0.0693 %	28 689 ₩

Name	Equities	%	Valuation
CLINOMICS INC. 1.31%	435,029	1.31%	541,907 $

Clinomics, Inc.

50 Unist-Gil, Building 251 Eonyang-eup

44919, Ulsan

http://www.clinomics.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
CLINOMICS INC.	-31.19%	42.74M
MODERNA, INC.	+21.04%	47.9B
LONZA GROUP AG	+46.56%	41.42B
IQVIA HOLDINGS INC.	-2.30%	40.7B
CELLTRION, INC.	-6.20%	28.92B
ICON PUBLIC LIMITED COMPANY	+10.73%	25.55B
ALNYLAM PHARMACEUTICALS, INC.	-21.57%	19.27B
BIO-TECHNE CORPORATION	-2.37%	12.15B
MEDPACE HOLDINGS, INC.	+31.18%	12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.82%	11.99B

Other Biotechnology & Medical Research